Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | CPT2 | P23786 | 2/20 | 0.47 |
| ▸ | CPT1A | P50416 | 2/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146209 | 0.87 | HTR6 (0.51) | HTR6HTR1ADRD2ALDH1A1MAPK1 | |
| SCHEMBL3363394 | 0.84 | HTR6 (0.52) | HTR6HTR1ADRD2PKMTSHR | |
| SCHEMBL8652798 | 0.79 | CPT1A (0.63) | HTR6CPT2CPT1ACPT1BALDH1A1 | |
| SCHEMBL3363534 | 0.79 | FGFR4 (0.51) | HTR6HTR1ADRD2TSHRFGFR4 | |
| SCHEMBL17927571 | 0.76 | HTR6 (0.77) | HTR6HTR1ADRD2ALDH1A1PKM | |
| SCHEMBL3133305 | 0.76 | CPT1A (0.54) | HTR6HTR1ADRD2CPT2CPT1A | |
| SCHEMBL1643417 | 0.75 | KMO (0.68) | KMOALDH1A1TSHRPOLB | |
| SCHEMBL17927508 | 0.72 | HTR6 (0.57) | HTR6HTR1ADRD2ALDH1A1PKM | |
| SCHEMBL60648 | 0.72 | KMO (0.67) | KMOALDH1A1MAPK1TP53PKM | |
| Hydrochloric Acid SCHEMBL6186324 | 0.71 | KMO (0.65) | KMOALDH1A1MAPK1TP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118060-B1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2010-10-06 | — | — | EP | claimed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | claimed |
| EP-2118060-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2009-11-18 | — | — | EP | claimed |
| WO-2008095908-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | claimed |
| EP-2118060-B1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| EP-2118060-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008095908-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | CCR9, IDO1, CCR10 | HTR6 85/4885HTR1A 164/4885DRD2 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.